Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band ± 20%
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.It is an India-based company engaged in manufacturing active pharmaceutical ingredients.The Companys segments include bulk chemicals, finished dosage formulations, retail pharmacy and job work charges. The Companys products in the oncology segment include Desifer, Veenat, Bendit, Bortenat, Lenalid and Clokeran. The Companys product offerings in the pharma segment include T-Score, PT-MaX, Glatimer, Tarana and Tigi. The Company operates in India, United States of America, Europe and the rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Hyderabad, Telangana
- Chairman
- V C Nannapaneni
- CEO & MD
- V C Nannapaneni
- Registrar
- Venture Capital & Corporate Investments Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE987B01026
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Natco Pharma Ltd today?
Natco Pharma Ltd (NATCOPHARM) is trading at ₹791.85. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is NATCOPHARM’s P/E ratio versus the sector?
NATCOPHARM trades at a P/E of 16.8. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is NATCOPHARM’s dividend yield?
NATCOPHARM has a dividend yield of 0.60%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is NATCOPHARM’s 52-week high and low?
NATCOPHARM has traded between ₹773.6 and ₹1,226.8 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Natco Pharma Ltd?
Natco Pharma Ltd has a market capitalisation of ₹15,002 crore.
▶What is NATCOPHARM’s return on equity?
NATCOPHARM reports a return on equity of 16.4%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are NATCOPHARM’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is NATCOPHARM’s promoter holding?
Promoters hold 49.41% of NATCOPHARM. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include NATCOPHARM?
Index membership is listed in the Context block on this page, along with the weight NATCOPHARM carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Natco Pharma Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from NATCOPHARM’s own numbers. The judgement is yours.
NATCOPHARM at a glance
Natco Pharma Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Natco Pharma Ltd (NATCOPHARM) last traded at ₹791.85, giving it a market capitalisation of ₹15,002 crore. The 52-week range is ₹773.6 to ₹1,226.8, and the price is 4% of the way up that range. It trades at a price-to-earnings ratio of 16.8. Promoters hold 49.41% of the company in the latest shareholding filing.
| Market cap | ₹15,002 crore |
|---|---|
| P/E | 16.8 |
| ROE | 16.4% |
| ROCE | 16.8% |